Objective: To evaluate and compare the effects of metformin used as a single-agent therapy and in combination with gliclazide modified release (MR) on glycoregulation and lipid profile in patients with type 2 diabetes mellitus (T2DM).
Methodology: A multi-center observational epidemiological study was carried out in patients with T2DM, divided in two groups according to the current type of treatment: first group was on monotherapy with metformin in daily dose (DD) of 2.000 mg while second group was treated with metformin in same DD plus gliclazide MR 60 mg per day. Anthropometric measurements, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) and lipid profile (cholesterol, tryglicerides, HDL, LDL) were evaluated and statistically analyzied.
Results: A total of 105 patients were enrolled of whom 59 (56.2%) were treated with metformin (mean age 59.62 years, range of 4078 years, SD 9.08; male: female=27:32 patients) while 46 (43.8%) were on combined therapy with metformin plus gliclazide MR (mean age 60.24 years, range of 3677 years, SD 10.13; male: female=19:27 patients). No significant difference was observed between groups regarding age (t test, P=0.744) and gender (Pearson chi square test, P=0.648). Patients with metformin had higher body mass index (BMI), with mean BMI of 30.74 kg/m2 compared to 27.99 kg/m2 (t test, P=0.004). No significant difference was registrated regarding FPG (t test, P=0.917) and plasma lipids while patients with combined therapy had higher levels of HbA1c (t test, P=0.032) and worse glycoregulation (Pearson chi square test, P=0.021).
Conclusion: In patients with T2DM requiring combination therapy, a tight follow-up through various modalities in needed in order to achive and maintain an adequate glycaemic control.
18 - 21 May 2019
European Society of Endocrinology